User profiles for Svitlana Prylutska
Світлана Прилуцька (Svitlana Prylutska)НУБіП (Національний університет біоресурсів і природокористування України)/ NULES … Verified email at nubip.edu.ua Cited by 2979 |
C60 Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment
S Prylutska, I Grynyuk, O Matyshevska, Y Prylutskyy… - Drugs in R&D, 2014 - Springer
Background Doxorubicin (Dox) is one of the most potent anticancer drugs, but its successful
use is hampered by high toxicity caused mainly by generation of reactive oxygen species. …
use is hampered by high toxicity caused mainly by generation of reactive oxygen species. …
Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy
SV Prylutska, LM Skivka, GV Didenko… - Nanoscale Research …, 2015 - Springer
The main aim of this work was to evaluate the effect of doxorubicin in complex with C 60
fullerene (C 60 + Dox) on the growth and metastasis of Lewis lung carcinoma in mice and to …
fullerene (C 60 + Dox) on the growth and metastasis of Lewis lung carcinoma in mice and to …
In vitro and in vivo toxicity of pristine C60 fullerene aqueous colloid solution
Toxicity of the C 60 fullerene aqueous colloid solution in vitro and in vivo experiments was
studied. C 60 fullerene in the concentration range of 3.6–144 µg/mL demonstrated low toxicity …
studied. C 60 fullerene in the concentration range of 3.6–144 µg/mL demonstrated low toxicity …
A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity
S Prylutska, S Politenkova… - Beilstein journal of …, 2017 - beilstein-journals.org
The self-organization of C 60 fullerene and cisplatin in aqueous solution was investigated
using the computer simulation, dynamic light scattering and atomic force microscopy …
using the computer simulation, dynamic light scattering and atomic force microscopy …
Toxicity of C60 fullerene–cisplatin nanocomplex against Lewis lung carcinoma cells
Cisplatin (Cis-Pt) is the cytotoxic agent widely used against tumors of various origin, but its
therapeutic efficiency is substantially limited by a non-selective effect and high toxicity. …
therapeutic efficiency is substantially limited by a non-selective effect and high toxicity. …
C60 fullerene enhances cisplatin anticancer activity and overcomes tumor cell drug resistance
We formulated and analyzed a novel nanoformulation of the anticancer drug cisplatin (Cis)
with C 60 fullerene (C 60 +Cis complex) and showed its higher toxicity toward tumor cell lines …
with C 60 fullerene (C 60 +Cis complex) and showed its higher toxicity toward tumor cell lines …
[HTML][HTML] C60 fullerene accumulation in human leukemic cells and perspectives of LED-mediated photodynamic therapy
Recent progress in nanobiotechnology has attracted interest to a biomedical application of
the carbon nanostructure C 60 fullerene since it possesses a unique structure and versatile …
the carbon nanostructure C 60 fullerene since it possesses a unique structure and versatile …
Synergy of Chemo- and Photodynamic Therapies with C60 Fullerene-Doxorubicin Nanocomplex
A nanosized drug complex was explored to improve the efficiency of cancer chemotherapy,
complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts …
complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts …
Study of C60 fullerenes and C60-containing composites cytotoxicity in vitro
SV Prylutska, OP Matyshevska, AA Golub… - Materials Science and …, 2007 - Elsevier
Influence of C 60 fullerenes and C 60 containing composites on the basis of aminopropylaerosil
on erythrocytes resistance to the acid haemolysis and viability of thymocytes, Erlich …
on erythrocytes resistance to the acid haemolysis and viability of thymocytes, Erlich …
Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro
Conventional anticancer chemotherapy is limited because of severe side effects as well as
a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have …
a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have …